Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Meiji, Daito to Launch Talks on New Consortium to Stabilize Generic Supply, Boost Profitability
June 6, 2025
- Keytruda Japan’s Top-Selling Drug for 20th Month Running: Encise
June 6, 2025
- Santen’s Myopia Drug Approved in Europe
June 6, 2025
- Towa/CiRA to Launch PII/III Trial of Bromocriptine for Familial AD
June 5, 2025
- Fuji Keizai Issues 2040 Market Outlook for Dermatology, Collagen Diseases and More
June 5, 2025
- Takeda’s Adcetris Widens Label in Europe
June 5, 2025
- Enhertu Entering New Phase of Growth with Early-Line Breast Cancer Data: CEO
June 4, 2025
- Sawai Cuts FY2024 Results after Remitch Ruling, Net Profit Drops by Half
June 4, 2025
- Dupixent’s COPD Use Expected to Benefit Patients with Allergic Symptoms: Professor
June 3, 2025
- Kaken to Codevelop TWOCELLS’ Cell Therapy in Japan
June 3, 2025
- Taiho Out-Licenses LSD1 Inhibitor to Yokohama Upstart
June 3, 2025
- Nxera-Lilly Collab Hits Key Milestone, Triggers Undisclosed Payment
June 3, 2025
- Enhertu Extends Survival as 2nd-Line Gastric Cancer Therapy
June 3, 2025
- Kura/Kyowa Kirin’s AML Drug Accepted for US FDA Review
June 3, 2025
- Fuso Sets Up 8 Billion Yen Credit Line after Remitch Ruling
June 3, 2025
- Bayer Files Low-Dose MRI Contrast Agent Gadoquatrane in Japan
June 3, 2025
- Servier Launches Tibsovo for IDH1-Mutated AML in Japan
June 3, 2025
- Scemblix’s 1st Line Nod Will Take CML Therapy to New Stage: Professor
June 2, 2025
- Shionogi’s OIC Med Naldemedine Accepted for Review in China
June 2, 2025
- Astellas Nabs Rights to China Firm’s CLDN18.2 ADC
June 2, 2025
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…